银屑病关节炎全身治疗的系统评价、Meta分析与GRADE评估
该研究系统检索三个数据库至2017年9月,纳入20项试验,评估获批全身药物治疗银屑病关节炎的疗效与安全性,采用GRADE分级。结果显示抗TNF抗体、乌司奴单抗、IL-17抗体和阿普司特对ACR20/50等结局有效,但多数证据质量为中至低;来氟米特、甲氨蝶呤和柳氮磺吡啶在安慰剂对照中未显示ACR统计学优势。
要点
- 抗TNF抗体、乌司奴单抗、IL-17抗体和阿普司特对银屑病关节炎有效。
- 来氟米特、甲氨蝶呤和柳氮磺吡啶在安慰剂对照中未显示ACR统计学优势。
- 多数疗效证据质量为中至低,安全性证据质量多为低。
核心结论
- 除抗TNF抗体和乌司奴单抗外,IL-17抗体和阿普司特对银屑病关节炎也有效。
- 基于各一项比较试验,抗IL-17抗体似乎与抗TNF抗体疗效相当,阿普司特尚不明确。
研究设计与样本
- 系统评价与Meta分析,检索三个数据库(最后更新2017年9月),纳入20项试验。
- 提取16-24周后的ACR20/50、HAQ-DI、SF-36及不良/严重不良事件数据,采用GRADE评估证据质量。
主要发现
- ACR20:英夫利西单抗+甲氨蝶呤 vs 甲氨蝶呤 RR 1.40(95%CI 1.07-1.84),证据质量极低。
- ACR20:依奇珠单抗每2周 vs 阿达木单抗每2周 RR 1.08(95%CI 0.86-1.36),证据质量极低。
- ACR20:来氟米特 vs 甲氨蝶呤 RR 1.01(95%CI 0.84-1.21),证据质量低。
- 18项药物 vs 安慰剂比较中,15项对ACR20/50、HAQ-DI和SF-36的疗效证据质量为中至低。
- 三项安慰剂对照中,来氟米特、甲氨蝶呤和柳氮磺吡啶对ACR未显示统计学优势。
关键数值与推荐
- ACR20应答率:英夫利西单抗+甲氨蝶呤 vs 甲氨蝶呤 RR 1.40(95%CI 1.07-1.84)。
- ACR20应答率:依奇珠单抗每2周 vs 阿达木单抗每2周 RR 1.08(95%CI 0.86-1.36)。
- ACR20应答率:来氟米特 vs 甲氨蝶呤 RR 1.01(95%CI 0.84-1.21)。
临床怎么用
- 临床可选用抗TNF抗体、乌司奴单抗、IL-17抗体或阿普司特治疗银屑病关节炎。
- 来氟米特、甲氨蝶呤和柳氮磺吡啶在部分安慰剂对照试验中未显示ACR统计学优势,需结合具体情况使用。
局限性
- 仅检索至2017年9月,未纳入此后发表的研究。
- 多数比较的证据质量仅为中至低,部分为极低。
- 抗IL-17抗体与抗TNF抗体的比较仅基于各一项试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Twenty per cent of patients with plaque psoriasis also have psoriatic arthritis - a disease affecting joints and entheses. Different treatment options exist but currently no succinct systematic overview exists. A systematic review of approved systemic treatments for psoriatic arthritis was conducted. We systematically searched in three databases (last update September 2017). Data were extracted for ACR20/50, HAQ-DI, SF-36 and adverse/serious adverse events after 16-24 weeks. We assessed the quality of evidence using GRADE. Twenty trials were included. Three trials compared two active substances. Results for ACR20 were infliximab + methotrexate vs. methotrexate: RR 1.40 (95% CI 1.07-1.84) very low quality evidence; ixekizumab Q2W vs. adalimumab Q2W: RR 1.08 (95% CI 0.86-1.36) very low quality, leflunomide vs. methotrexate: RR 1.01, (95% CI 0.84-1.21) low quality. Eighteen drug vs. placebo comparisons were included. For ACR20/50, HAQ-DI and SF-36, the active treatment was efficacious and the quality of the evidence was mostly moderate to low (15 of 18 comparisons). The quality of evidence for (serious) adverse events was mostly low; differences were rare. In three placebo-controlled comparisons, leflunomide, MTX and sulfasalazine failed to show statistical superiority for ACR. Besides the established treatment of anti-TNF antibodies and ustekinumab for psoriatic arthritis, the newer treatment options of IL17 antibodies and apremilast are also effective for the treatment of psoriatic arthritis. Based on just one comparative trial and one drug each, the new class of anti-IL 17 antibodies appears to be equally effective as the group of anti-TNF antibodies; for apremilast, this is yet unclear.
引用
- Dressler C, Eisert L, Pham PA, et al. Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta-analysis and GRADE evaluation. J Eur Acad Dermatol Venereol. 2019. PMID: 30735612. doi:10.1111/jdv.15482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。